['type 1 diabetes mellitus']
['biochaperone insulin lispro', 'humalog®']

        Inclusion Criteria:

          -  Type 1 diabetes for at least 12 months

          -  Body Mass Index (BMI) between 18.5 and 28.5 kg/m^2, both inclusive

          -  Using or having used a Roche CSII system (Accu-Chek® Spirit Combo/ Accu- Chek® Spirit)
             for at least 6 months before screening. In Part B subjects using any form of CSII
             treatment for at least 6 months before screening will be included.

          -  HbA1c <= 9.0%.

          -  Total insulin dose of < 1.2 (I)U/kg/day

          -  Ability to calculate insulin bolus manually or using a bolus calculator and
             willingness to consume regular meals, perform carbohydrate counting, self-monitoring
             of plasma glucose (SMPG) profiles and use of Continuous Glucose Monitoring (CGM).

          -  Fasting C-peptide <= 0.30 nmol/L

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to Investigational Medicinal Product(s) (IMP(s))
             or related products

          -  Type 2 diabetes mellitus

          -  Previous participation in this trial.

          -  Receipt of any investigational product in a clinical trial within 60 days before
             randomisation in this trial

          -  Clinically significant abnormal haematology, biochemistry, urinalysis, or coagulation
             screening test

          -  Presence of clinically significant acute gastrointestinal symptoms

          -  Known slowing of gastric emptying and or gastrointestinal surgery

          -  Unusual meal habits and special dietary requirements or unwillingness to eat the food
             provided in the trial

          -  History of diabetic ketoacidosis (DKA) episodes requiring hospitalization within 6
             months prior to screening

          -  History of abscess at the infusion site within 6 months prior to screening

          -  Hypoglycaemia unawareness as judged by the Investigator

          -  History of severe hypoglycaemic episodes requiring hospitalization within the last 6
             months prior to screening
      